gilead
Gilead Dispute
Wednesday, 07 July 2004
KEI asks US Federal Trade Commission to Investigate Gilead effort to control market for AIDS drugs ingredients: (press release, complaint).
KEI asks FTC to Investigate Gilead Effort To Control Market For AIDS Drugs Ingredients
Press Release
15 Feb 07
FMI James Love +1.202.332.2670, cell +1.202.361.3040, james.love@keionline.org
(See attachment for patent and health experts contact information)
FTC ASKED TO INVESTIGATE GILEAD EFFORT TO CONTROL MARKET FOR AIDS DRUGS INGREDIENTS
[Complaint available here:
http://www.keionline.org/misc-docs/ftcgilead12feb07.pdf ]
Amendment to the Gilead-Ranbaxy License Agreement
Submitted by Judit Rius on 9. June 2008 - 12:00We have received a copy of an amendment to the September 2006 voluntary License Agreement between Gilead Sciences, Inc and Ranbaxy Laboratories, Ltd concerning the manufacture and sale of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine for the treatment of HIV-AIDS.
Andrew Pollack on Gilead’s $130 pill for pulmonary arterial hypertension
Submitted by James Love on 17. June 2007 - 8:44This is Andrew Pollack’s recent story on Gilead’s new $130 per pill (use daily) for pulmonary arterial hypertension. The price of this drug, which is a once daily pill, is roughly the average per capita income in the United States, leaving nothing else for food, housing, clothing or having a beer at the local bar.
